FDA Revises Its Fiscal 2022 GDUFA Science and Research Priorities

The FDA has revised its fiscal 2022 Generic Drug User Fee Act (GDUFA) II research priorities based on feedback gleaned from a June public workshop in which generic drugmakers critiqued the agency’s fiscal 2021 initiatives.
Source: Drug Industry Daily